Dissolution Enhancement of Tadalafil Tablets by the complex method of betacyclodextrin inclusion and variation of disintegrating excipients
Abstract
Tadalafil (TDL) is a drug clinically proven to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary hypertension. TDL is classified as a BCS Class II drug, which means it has high permeability but low solubility. Solubility enhancement is achieved through the inclusion complex method and verified by dissolution testing. This study aims to determine the dissolution profile of tadalafil inclusion complex tablets using the β-cyclodextrin (βCD) inclusion complex method with disintegrant variations. The results show that the tablet hardness is: R1 = 6.6 ± 0.5 kgf, R2 = 6.48 ± 1.4 kgf, and R3 = 6.6 ± 1.3 kgf. The disintegration time evaluation shows: R1 = 4.66 ± 1.08 minutes, R2 = 5.08 ± 0.91 minutes, and R3 = 5.1 ± 1.1 minutes. Each formulation's tensile strength test results are: R1 = 1.3 MPa, R2 = 1.3 MPa, and R3 = 1.1 MPa. The average drug content in the inclusion complex tablets is: R1 = 104.11 ± 1%, R2 = 106.23 ± 0.1%, and R3 = 105.09 ± 1.9%. The dissolution profile of the inclusion complex tablets at the 30-minute mark is: R1 = 85.2 ± 4.2%, R2 = 79.7 ± 3.6%, and R3 = 77.4 ± 5.3%. Variations in disintegrants significantly affect the dissolution profile during the early minutes, which impacts the overall dissolution profile. The TDL-βCD inclusion complex method successfully achieved the Q value by the monograph specifications.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.